Othera Pharmaceuticals Inc.

	About Othera Management Board of Directors Scientific Advisory Board Clinical Advisory Board Collaborations History Mechanism Intellectual Property Pipeline OT–551: Dry AMD OT–730: Glaucoma OT–304: Cancer and Inflammatory Diseases Press Releases In the News Resources Careers Clinical Trials Contact Directions
	RECENT NEWS 10.01.07: Othera Pharmaceuticals Appoints Dr. Frederick Rickles as Chief Science Officer 06.18.07: Othera and NEI Reach Target Enrollment in Dry AMD Trial with OT-551 Eye Drops


In ophthalmics, we are developing novel topical eyedrop products that target age-related diseases, including some of the largest unmet medical needs in ophthalmology. Othera is also engaged in the discovery of a novel set of orally available compounds to address severe medical conditions including inflammatory and oncology-related diseases.